Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.
Abstract
Minor splicing is an under-appreciated splicing system required for the correct expression of ~700 genes in the human genome. This small subset of genes (0.35%) harbours introns containing non-canonical splicing sequences that are recognised uniquely by the minor spliceosome and cannot be processed by the major spliceosome. Using in vivo zebrafish and mouse cancer models, we show that heterozygous expression of Rnpc3 , encoding a unique protein component of the minor spliceosome, restricts the growth and survival of liver, lung and gastric tumours without impacting healthy cells. RNPC3 knockdown in human lung cancer-derived A549 cells also impairs cell proliferation and RNA-seq analysis reveals a robust and selective disruption to minor intron splicing and transcription-wide effects on gene expression. We further demonstrate that these perturbations are accompanied by DNA replication stress, DNA damage, accumulation of TP53 protein and activation of a Tp53-dependent transcriptional program that induces cell cycle arrest and apoptosis. Together our data reveal a vulnerability of cancer cells to minor splicing inhibition that restricts tumour growth.
Overview
CoChat Summary
TL;DR
Heterozygous loss or knockdown of the minor spliceosome component RNPC3/65K restricts growth and survival of liver, lung, gastric, and AML cancers in zebrafish and mouse models, largely without affecting healthy tissues. In A549 lung cancer cells, impaired minor splicing causes minor intron retention/alternative splicing, DNA replication stress and damage, TP53 stabilization, and a TP53-dependent program of cell cycle arrest, senescence, and apoptosis.
Key findings
- In a zebrafish krasG12V HCC model, rnpc3 heterozygosity reduced dox-induced liver enlargement from >5-fold to threefold, lowered adult liver/body weight from >12% to 7%, reduced EdU-positive hepatocytes from ~31% to 19% (40% reduction), and increased AnnexinV-mKate apoptotic foci by 40%.
- The zebrafish HCC effect depended on Tp53: rnpc3 heterozygosity reduced liver volume by 40% with WT tp53 but only 8% without functional Tp53; γ-H2AX-positive hepatocytes rose from 0.8% (WT/WT) to 4% in rnpc3 HETs and to 12.7% in rnpc3 HETs lacking WT Tp53.
- In mouse models, Rnpc3 heterozygosity reduced KrasG12D-driven lung tumor burden and Gp130F/F gastric adenoma weight at 100 and 180 days; ~40% of Rnpc3+/−;Gp130F/F mice had no corpus adenomas at 100 days, and pERK1/2 was decreased by 35%. In MLL-ENL AML, Rnpc3 recombination caused 95% loss of Rnpc3 mRNA, increased minor intron retention, and extended median survival by 52% (19 to 29 days) and 55% (22 to 34 days).
- In A549 cells, RNPC3 knockdown (~70%) reduced confluency by 30%; RNA-seq found 158/389 detected minor introns (40.6%) aberrantly spliced, with 134 (34.4%) elevated intron retention, 14 (3.6%) alternative splicing, and 10 (2.6%) both. IRFinder showed 60/599 minor introns (10%) with increased retention versus 148/179,463 major introns (0.08%), and U12 ASO caused a fivefold increase in γH2AX-positive cells, threefold more senescence, and G2 accumulation.
Methods
- In vivo cancer models: zebrafish TO(krasG12V) HCC with rnpc3 and tp53 genotypes, mouse KrasLSLG12D lung adenocarcinoma induced by intranasal AdCre, Gp130F/F gastric adenoma model with Tff1-CreERT2-induced Rnpc3 recombination, and MLL-ENL-GFP retroviral AML model using Rnpc3lox/lox;UBC-CreERT2 cells.
- In vitro human model: A549 lung adenocarcinoma cells transfected with RNPC3 or PDCD7 siRNAs or U12 ASO; assays included RT-qPCR/RT-PCR, RNA-seq, IRFinder, IPA, FACS for cell cycle/DNA damage/senescence, immunoblotting, and live-cell confluency.
- Statistics: Student’s t tests with Welch’s correction, one-way/two-way ANOVA with Tukey’s or Dunnett’s tests, Mantel–Cox for survival, and FDR control for RNA-seq; data generally shown as mean ± SEM.
Limitations
- The paper states that its multifaceted approach had disadvantages: focusing on fewer in vivo models might have demonstrated a formal link between Rnpc3 heterozygosity and aberrant minor splicing, which is absent from the current study.
- The paper states that in vivo gene dosing could only be reduced genetically by 50% or 100% (or not at all), making clinical extrapolation difficult; it predicts a therapeutic dose of RNPC3/65K inhibition would lie within the 50–100% range.
- The paper states that RNA-seq did not provide definitive evidence that mis-splicing of BRAF/RAF1/MAPK transcripts is responsible for decreased A549 growth/survival; evident from the text, the mechanistic work relies heavily on one human cell line (A549), and no small-molecule minor spliceosome inhibitor or patient-derived tumor data are presented.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
0 Valid · 0 Not valid · 13 Not checked · 127 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained with ASOs, where we demonstrated a dose-dependent inhibition of A549 cell growth.”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Discussion
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study complements these in vitro findings by demonstrating that heterozygous Rnpc3 expression is sufficient to reduce tumour burden in a variety of in vivo cancer models from zebrafish and mice, including those driven by mutant Kras oncogenes.”
- Also stated in: § Abstract · plain
“Using in vivo zebrafish and mouse cancer models, we show that heterozygous expression of Rnpc3, encoding a unique protein component of the minor spliceosome, restricts the growth and survival of liver, lung and gastric tumours without impacting healthy cells.”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Introduction
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also observed pERK1/2 staining at the luminal edge of adenomas in both the corpus and antral regions (Fig. 3H,I), indicating that the pro-proliferative MAPK pathway was active at the periphery of the growing adenomas.”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > Heterozygous loss of Rnpc3 reduces tumour burden in a STAT3-driven model of gastric adenocarcinoma
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed robust levels of EGFP-KrasG12V-GTP protein, which were not affected by the rnpc3 genotype (Fig. EV1A)”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > Heterozygous loss of rnpc3 reduces liver overgrowth in a krasG12V model of hepatocellular carcinoma
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases, transcripts from AML cells with a recombined Rnpc3 locus exhibited elevated minor intron retention compared to cells in which the Rnpc3 locus remained intact (Fig. 4D).”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > Disruption of the Rnpc3 locus in AML cells causes impaired minor splicing and prolonged survival of mice
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
87 more claims
Create a free account to see all 140 claims and to verify the 20 references still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 12
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This finding aligns with the known role of MIGs in executing oncogenic programs and our previous report linking enhanced minor intron splicing to metastatic progression.81,102,103”
From Identity rather than 3D position informs splicing of rare introns in the human genome (2026) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“This equates to an approximately 125% enrichment of minor intron retention over major intron retention (10% versus 0.08%) in response to RNPC3 knockdown.”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > RNPC3 knockdown in A549 cells selectively disrupts minor intron splicing over major intron splicing
Reported 125 · recomputed 12500
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > Heterozygous loss of rnpc3 reduces liver overgrowth in a krasG12V model of hepatocellular carcinoma
“we treated live zebrafish larvae (7 dpf) with the thymidine analogue, N-ethynyl-2’-deoxyuridine (EdU; 2 μM) for 2 h”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Methods > Cell cycle analysis in zebrafish
“Live zebrafish larvae (7 dpf) were incubated in 2 mM EdU in egg water for 2 h”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > Knockdown of RNPC3 impairs minor splicing and slows the growth of human A549 cells
“Of the 24,061 expressed transcripts, 2268 are DEGs”
§ Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers > Results > RNPC3 knockdown in A549 cells selectively disrupts minor intron splicing over major intron splicing
“Of the 24,644 transcripts detected, 583 (2.4%) were transcribed from MIGs (Fig. 5F,G).”
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data
Ramakers, C., Ruijter, J. M., Deprez, R. H. L., & Moorman, A. F. M. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01423-4 · Cited by 3,709
Liao, Y., Smyth, G. K., & Shi, W. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz114 · Cited by 2,936
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Cited by
The benchmarking and application of tag-degraders in vivo to validate therapeutic targets
Magtoto, C. M., Mieruszynski, S., Dong, H., Ng, A. P., Rago, L. D., Kueh, A. J., Brzozowski, M., Grohmann, C., Walker, J. R., Chua, N. K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73681-1 · Cited by 4
Self-citationIdentity rather than 3D position informs splicing of rare introns in the human genome
Springer, S. M., Fleck, K., Girardini, K. N., Riccard, S. M., Erceg, J., & Kanadia, R. N. (2026) · iScience · doi:10.1016/j.isci.2025.114532 · Cited by 2
Self-citationTaxonomy of introns, their evolution, and the role of minor introns in stress responsePreprint
Olthof, A. M., Schwoerer, C. F., Weber, A. L., Iswarya, A., Doggett, K., Mieruszynski, S., Cnaani, A., Heath, J. K., Biran, J., & Kanadia, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.12.511939 · Cited by 2
Self-citationAugspach, A., Francica, P., Girardini, K. N., Jaquet, M., Lehner, M., Rodríguez-Calero, A., Komarek, C., González-Fernández, M., Williams, H., Deng, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693392 · Cited by 1
Self-citationAlternative splicing as a multilayered regulatory hub in pancreatic ductal adenocarcinoma
Jiménez-Lozano, S., Hernández-Munaín, C., & Suñé, C. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.2009133
Metadata
- Authors
- Doggett, K., Morgan, K. J., Olthof, A. M., Mieruszynski, S., Williams, B. B., Garnham, A. L., Milevskiy, M. J. G., Whitehead, L., Coates, J., Buchert, M., O’Donoghue, R. J. J., Hall, T. E., Putoczki, T. L., Ernst, M., Sutherland, K. D., Kanadia, R. N., & Heath, J. K.
- Affiliations
- The University of Melbourne (AU)
- University of Copenhagen (DK)
- Walter and Eliza Hall Institute of Medical Research (AU)
- The University of Queensland (AU)
- University of Connecticut (US)
- Corresponding author
- Heath, Joan K
- ORCID
- Venue
- EMBO Reports
- Published
- 2025-07-07
- Volume
- 26
- Issue
- 15
- Pages
- 3937-3969
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC12332006
- OpenAlex
- W4412068648
- Semantic Scholar
- d38264c518ae5531d6fad77480962e1b2608093d
- Cited by
- 6
- References
- 68
- Citations by year
- 2026: 3 · 2025: 2
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- EMBO Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Australian Government Research Training Program Scholarship
- National Institute of Neurological Disorders and Stroke (R01NS102538)
- Federal Government | DHAC | National Health and Medical Research Council (1024878, 1161336)
- Ludwig Institute for Cancer Research (N/A)
- Victorian State Government Operational Support Grant (N/A)
- Australian Government NHMRC Independent Research Institutes Infrastructure Support Scheme
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- minor spliceosome, cancer vulnerability, tumor growth inhibition, lung cancer, liver cancer, gastric cancer, replication stress, DNA damage, cell cycle arrest, apoptosis, gene expression profiling, mouse tumor model
- MeSH terms
- A549 Cells, Animals, DNA Damage, Humans, Introns, Neoplasms, RNA Splicing, Zebrafish, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, RNA-Binding Proteins, Apoptosis, Spliceosomes, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. https://app.cochat.ai/papers/10.1038/s44319-025-00511-8
- The paper
- Doggett, K., Morgan, K. J., Olthof, A. M., Mieruszynski, S., Williams, B. B., Garnham, A. L., Milevskiy, M. J. G., Whitehead, L., Coates, J., Buchert, M., O’Donoghue, R. J. J., Hall, T. E., Putoczki, T. L., Ernst, M., Sutherland, K. D., Kanadia, R. N., & Heath, J. K. (2025). Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. EMBO Reports. https://doi.org/10.1038/s44319-025-00511-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.